UK markets open in 5 hours 58 minutes
  • NIKKEI 225

    29,403.40
    +241.60 (+0.83%)
     
  • HANG SENG

    28,842.13
    +103.23 (+0.36%)
     
  • CRUDE OIL

    71.23
    +0.35 (+0.49%)
     
  • GOLD FUTURES

    1,868.00
    +2.10 (+0.11%)
     
  • DOW

    34,393.75
    -85.85 (-0.25%)
     
  • BTC-GBP

    28,635.88
    +818.16 (+2.94%)
     
  • CMC Crypto 200

    1,010.43
    +41.59 (+4.29%)
     
  • ^IXIC

    14,174.14
    +104.72 (+0.74%)
     
  • ^FTAS

    4,074.57
    +6.24 (+0.15%)
     

Global Drug Delivery Partnering Deals Terms and Agreements Report 2021

·5-min read

Dublin, June 11, 2021 (GLOBE NEWSWIRE) -- The "Global Drug Delivery Partnering Terms and Agreements 2014-2021" report has been added to ResearchAndMarkets.com's offering.

The Global Drug Delivery Partnering Terms and Agreements 2014-2021 report provides comprehensive access to available deals and contract documents for over 1400 Drug Delivery deals.

The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.

The report presents financial deal term values for Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Drug Delivery partnering field; both the leading deal values and most active Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1400 online deal records of actual Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Drug Delivery partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Drug Delivery technologies and products.

Key benefits

Drug Delivery Partnering Terms and Agreements includes:

  • Trends in Drug Delivery dealmaking in the biopharma industry since 2014

  • Analysis of Drug Delivery deal structure

  • Access to headline, upfront, milestone and royalty data

  • Access to Drug Delivery contract documents

  • Leading Drug Delivery deals by value since 2014

  • Most active Drug Delivery dealmakers since 2014

In Global Drug Delivery Partnering Terms and Agreements 2014-2021, the available deals are listed by:

  • Company A-Z

  • Headline value

  • Stage of development at signing

  • Deal component type

  • Specific therapy target

  • Technology type

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the deal?

  • How are sales and payments audited?

  • What is the deal term?

  • How are the key terms of the agreement defined?

  • How are IPRs handled and owned?

  • Who is responsible for commercialization?

  • Who is responsible for development, supply, and manufacture?

  • How is confidentiality and publication managed?

  • How are disputes to be resolved?

  • Under what conditions can the deal be terminated?

  • What happens when there is a change of ownership?

  • What sublicensing and subcontracting provisions have been agreed?

  • Which boilerplate clauses does the company insist upon?

  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Drug Delivery dealmaking
2.1. Introduction
2.2. Drug Delivery partnering over the years
2.3. Most active Drug Delivery dealmakers
2.4. Drug Delivery partnering by deal type
2.5. Drug Delivery partnering by therapy area
2.6. Deal terms for Drug Delivery partnering
2.6.1 Drug Delivery partnering headline values
2.6.2 Drug Delivery deal upfront payments
2.6.3 Drug Delivery deal milestone payments
2.6.4 Drug Delivery royalty rates

Chapter 3 - Leading Drug Delivery deals
3.1. Introduction
3.2. Top Drug Delivery deals by value

Chapter 4 - Most active Drug Delivery dealmakers
4.1. Introduction
4.2. Most active Drug Delivery dealmakers
4.3. Most active Drug Delivery partnering company profiles

Chapter 5 - Drug Delivery contracts dealmaking directory
5.1. Introduction
5.2. Drug Delivery contracts dealmaking directory

Chapter 6 - Drug Delivery dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Drug Delivery deals by company A-Z
Appendix 2 - Drug Delivery deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Drug Delivery deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 - Drug Delivery deals by therapy area
Appendix 5 -Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/r/k6jmm8

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900